Lorlatinib/lorlatinib is developed and produced by which company

Lorlatinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor developed and produced by Pfizer Inc., a world-renowned pharmaceutical company. The development of this drug aims to overcome the resistance problems faced by the first two generations of ALK inhibitors during treatment, especially to provide more powerful and penetrating treatments when patients have brain metastases or target mutations. Pfizer has long-term accumulation and rich experience in the field of molecularly targeted drugs, and lorlatinib is a key part of this strategic layout.

Pfizer used advanced structure optimization technology in the development of lorlatinib, which gave it a higher affinity for theALK mutation site at the molecular level and good penetration into the central nervous system. This makes the drug significantly more effective than previous-generation drugs in patients with brain metastases. Lorlatinib has received priority review status from regulatory agencies in multiple countries and regions and has been approved for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC), especially in the sequential regimen after failure of first- and second-generation ALK inhibitors such as crizotinib, alectinib or ceritinib.

In terms of product production, Pfizer currently mainly completes the pharmaceutical process of lorlatinib in the United States and multiple of its globalGMP certified production bases. These bases are equipped with strict quality control systems to ensure that drugs meet international pharmacopoeia standards in terms of batch stability, purity, content, etc. In addition, Pfizer is also actively expanding the registration and distribution network of lorlatinib in the Asian and European markets to further meet the medication needs of patients in different countries and regions.

References：https://www.lorbrena.com/